China Sxt Pharmaceuticals Inc (SXTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 09-2024 | 03-2024 | 09-2023 | 03-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,304 | -803 | -3,099 | -9,696 | -5,935 |
| Depreciation Amortization | 82 | 69 | 203 | 103 | 250 |
| Accounts receivable | N/A | -303 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | 330 | N/A | N/A | N/A |
| Other Working Capital | -972 | -746 | -382 | 316 | 1,416 |
| Other Operating Activity | 1,849 | 97 | 1,350 | 8,697 | 4,188 |
| Operating Cash Flow | $-2,345 | $-1,357 | $-1,928 | $-580 | $-81 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 64 | 41 | -7 | N/A | -71 |
| Other Investing Activity | 0 | 0 | 34 | 20 | 58 |
| Investing Cash Flow | $64 | $41 | $26 | $20 | $-12 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 1,171 | N/A | N/A | N/A |
| Debt Repayment | N/A | -146 | N/A | N/A | N/A |
| Other Financing Activity | 8,399 | 6,212 | -2,624 | -4,462 | 2,942 |
| Financing Cash Flow | $8,399 | $7,237 | $-2,624 | $-4,462 | $2,942 |
| Exchange Rate Effect | -65 | 515 | -765 | -882 | -1,050 |
| Beginning Cash Position | 12,077 | 12,077 | 17,368 | 17,368 | 15,570 |
| End Cash Position | 18,129 | 18,513 | 12,077 | 11,465 | 17,368 |
| Net Cash Flow | $6,052 | $6,436 | $-5,291 | $-5,903 | $1,799 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,345 | -1,357 | -1,928 | -580 | -81 |
| Capital Expenditure | N/A | 41 | N/A | N/A | N/A |
| Free Cash Flow | -2,345 | -1,317 | -1,928 | -580 | -81 |